Riccardo Perfetti net worth and biography

Riccardo Perfetti Biography and Net Worth

Insider of Applied Therapeutics

Riccardo Perfetti, M.D., Ph.D. has served as Chief Medical Officer of Applied Therapeutics since August 2018. Before joining us, Dr. Perfetti served as a Senior Medical Officer, Vice President and Head of Global Medical Affairs, Diabetes and Cardiovascular Business Unit at Sanofi S.A., a publicly traded pharmaceutical company, from October 2007 to August 2018. Prior to joining Sanofi, Dr. Perfetti served in various roles at Amgen Inc., a publicly traded biopharmaceutical company, including as a Director and Global Development Leader in diabetes, obesity, metabolism and endocrinology from December 2004 to August 2007. Dr. Perfetti was previously an associate professor of medicine at University of California in Los Angeles and a professor of medicine at the National Institutes of Health (NIH). Dr. Perfetti practiced as an endocrinologist at Cedars-Sinai Medical Center and also served as Director of the Diabetes Research Laboratory and Director of the Outpatient Diabetes Program. Dr. Perfetti received his M.D. and Ph.D. in Endocrinology from University La Sapienza in Rome, Italy and received post-graduate training in endocrinology and molecular biology at NIH.

What is Riccardo Perfetti's net worth?: The estimated net worth of Riccardo Perfetti is at least $284.93 thousand as of March 4th, 2025. Dr. Perfetti owns 890,409 shares of Applied Therapeutics stock worth more than $284,931 as of June 23rd. This net worth evaluation does not reflect any other investments that Dr. Perfetti may own. Additionally, Dr. Perfetti receives a salary of $860,760.00 as Insider at Applied Therapeutics. Learn More about Riccardo Perfetti's net worth.
How old is Riccardo Perfetti?: Dr. Perfetti is currently 63 years old. There are 5 older executives and no younger executives at Applied Therapeutics. Learn More on Riccardo Perfetti's age.
What is Riccardo Perfetti's salary?: As the Insider of Applied Therapeutics Inc., Dr. Perfetti earns $860,760.00 per year. The highest earning executive at Applied Therapeutics is Dr. Shoshana Shendelman Ph.D., Chair of the Board of Directors, Founder, President, CEO & Secretary, who commands a salary of $946,080.00 per year. Learn More on Riccardo Perfetti's salary.
How do I contact Riccardo Perfetti?: The corporate mailing address for Dr. Perfetti and other Applied Therapeutics executives is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. Applied Therapeutics can also be reached via phone at (212) 220-9226 and via email at [email protected]. Learn More on Riccardo Perfetti's contact information.
Has Riccardo Perfetti been buying or selling shares of Applied Therapeutics?: Riccardo Perfetti has not been actively trading shares of Applied Therapeutics over the course of the past ninety days. Most recently, Riccardo Perfetti sold 10,366 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $0.44, for a transaction totalling $4,561.04. Following the completion of the sale, the insider now directly owns 890,409 shares of the company's stock, valued at $391,779.96. Learn More on Riccardo Perfetti's trading history.
Who are Applied Therapeutics' active insiders?: Applied Therapeutics' insider roster includes Riccardo Perfetti (Insider), Shoshana Shendelman (CEO), and Charles Silberstein (CFO). Learn More on Applied Therapeutics' active insiders.
Are insiders buying or selling shares of Applied Therapeutics?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 452,907 shares worth more than $2,521,735.17. The most recent insider tranaction occured on March, 4th when insider Riccardo Perfetti sold 10,366 shares worth more than $4,561.04. Insiders at Applied Therapeutics own 1.6% of the company. Learn More about insider trades at Applied Therapeutics.
Information on this page was last updated on 3/4/2025.

Riccardo Perfetti Insider Trading History at Applied Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2025	Sell	10,366	$0.44	$4,561.04	890,409
6/6/2024	Sell	22,003	$4.32	$95,052.96	1,009,534
3/14/2024	Sell	110,804	$5.39	$597,233.56	1,031,537
11/30/2023	Sell	1,583	$1.97	$3,118.51	692,341
9/27/2023	Sell	10,932	$2.70	$29,516.40	693,924
1/11/2023	Sell	6,053	$0.91	$5,508.23	154,856
3/23/2022	Buy	30,000	$1.97	$59,100.00
3/21/2022	Buy	12,548	$1.85	$23,213.80
8/9/2021	Sell	15,000	$17.39	$260,850.00	15,000
7/28/2021	Sell	15,000	$17.50	$262,500.00	15,000
7/15/2021	Sell	460	$19.54	$8,988.40
7/13/2021	Sell	460	$21.25	$9,775.00
6/7/2021	Sell	460	$20.97	$9,646.20	460
6/4/2021	Sell	460	$19.65	$9,039.00	460
5/25/2021	Sell	460	$17.97	$8,266.20	1,640
5/11/2021	Sell	200	$17.27	$3,454.00	200
4/30/2021	Sell	2,560	$18.39	$47,078.40	1,640
4/28/2021	Sell	1,640	$18.44	$30,241.60	1,640
4/14/2021	Sell	200	$17.11	$3,422.00	200
3/30/2021	Sell	460	$18.43	$8,477.80	465
3/26/2021	Sell	465	$19.68	$9,151.20	465
3/15/2021	Sell	465	$19.61	$9,118.65	465
3/12/2021	Sell	465	$19.38	$9,011.70	465
2/25/2021	Sell	1,295	$23.20	$30,044.00	465
2/23/2021	Sell	465	$21.84	$10,155.60	465
2/3/2021	Sell	1,295	$26.79	$34,693.05	3,785
2/1/2021	Sell	1,460	$25.30	$36,938.00	3,785
1/21/2021	Sell	465	$20.30	$9,439.50	465
1/19/2021	Sell	465	$21.83	$10,150.95	465
1/8/2021	Sell	16,515	$23.23	$383,643.45	7,765
1/6/2021	Sell	7,765	$23.47	$182,244.55	7,765
12/29/2020	Sell	465	$21.95	$10,206.75	465
12/9/2020	Sell	465	$20.46	$9,513.90	465
12/7/2020	Sell	465	$20.49	$9,527.85	465
11/23/2020	Sell	465	$20.59	$9,574.35	1,660
11/20/2020	Sell	1,660	$19.07	$31,656.20	1,660
11/10/2020	Sell	200	$17.59	$3,518.00	200
10/29/2020	Sell	465	$17.27	$8,030.55	465
10/27/2020	Sell	465	$21.20	$9,858.00	465

Riccardo Perfetti Buying and Selling Activity at Applied Therapeutics

Applied Therapeutics Company Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Today's Range

Now: $0.32

$0.31

$0.35

50 Day Range

MA: $0.39

$0.30

$0.60

2 Week Range

Now: $0.32

$0.30

$10.62

Volume

2,303,458 shs

Average Volume

3,382,462 shs

Market Capitalization

$45.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Riccardo Perfetti Biography and Net Worth

What is Riccardo Perfetti's net worth?

How old is Riccardo Perfetti?

What is Riccardo Perfetti's salary?

How do I contact Riccardo Perfetti?

Has Riccardo Perfetti been buying or selling shares of Applied Therapeutics?

Who are Applied Therapeutics' active insiders?

Are insiders buying or selling shares of Applied Therapeutics?